Triptorelin

At a glance

Overview

Triptorelin is used in separate oncology and pediatric formulations with different clinical objectives. In prostate cancer, lowering testosterone reduces stimulation of androgen-dependent disease. In central precocious puberty, suppression of early gonadotropin activation slows premature pubertal progression. Although the active peptide is shared, the product, formulation, labeled population and follow-up requirements are specific. Depot delivery maintains prolonged exposure and cannot be understood as an occasional physiological GnRH pulse. Additional triptorelin products and indications exist outside the United States; local labeling should be checked rather than assuming a brand name carries identical uses everywhere.

Supporting sources [1] [2] [3]

How it works

Triptorelin initially stimulates pituitary GnRH receptors, increasing release of LH and FSH. Continued exposure then suppresses receptor responsiveness and gonadotropin secretion, reducing testosterone or ovarian estrogen. This delayed suppressive action produces an early flare that differs from the immediate blockade of GnRH antagonists. The eventual fall in sex steroids explains both therapeutic action and consequences such as hot flushes and effects on bone health.

Supporting sources [1] [2] [3]

How do the approved products differ?

Trelstar is labeled for advanced prostate cancer. Triptodur is labeled for central precocious puberty in pediatric patients aged two years and older. The distinction involves more than packaging: the populations, treatment goals, formulation instructions and monitoring endpoints differ and must follow the relevant prescribing information.

Supporting sources [1] [2]

What did comparative prostate-cancer research show?

A randomized study of 284 men compared triptorelin with leuprolide. Both maintained low testosterone effectively, although initial suppression developed at different rates. The trial supports the drug’s androgen-deprivation effect; its results should not be generalized into a definitive claim that triptorelin is superior for long-term cancer survival.

Supporting sources [3]

What risks are important in adults and children?

An early flare can worsen prostate-cancer symptoms. Adult labeling also addresses metabolic and cardiovascular risks, QT prolongation and seizures. Pediatric labeling includes psychiatric symptoms and intracranial hypertension. Severe skin reactions are another GnRH-agonist concern. Follow-up must assess the individual disease, hormonal response and adverse effects.

Supporting sources [1] [2]

Can the prostate-cancer and pediatric depots be substituted?

A shared active ingredient does not make these preparations interchangeable. They have distinct formulation and indication instructions. In children, clinical and biochemical confirmation of central precocious puberty is essential; in adults, androgen suppression must fit the broader prostate-cancer plan and symptom assessment.

Supporting sources [1] [2]